Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43


Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition.

van Cruijsen H, Oosterhoff D, Lindenberg JJ, Lougheed SM, Fehres C, Weijers K, van Boerdonk R, Giaccone G, Scheper RJ, Hoekman K, de Gruijl TD.

Immunotherapy. 2011 Sep;3(9):1051-61. doi: 10.2217/imt.11.107.


Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells.

McFarland BC, Gray GK, Nozell SE, Hong SW, Benveniste EN.

Mol Cancer Res. 2013 May;11(5):494-505. doi: 10.1158/1541-7786.MCR-12-0528. Epub 2013 Feb 5.


Human melanoma cells inhibit the earliest differentiation steps of human Langerhans cell precursors but failed to affect the functional maturation of epidermal Langerhans cells.

Berthier-Vergnes O, Gaucherand M, Péguet-Navarro J, Plouet J, Pageaux JF, Schmitt D, Staquet MJ.

Br J Cancer. 2001 Dec 14;85(12):1944-51.


In vitro differentiation of CD34+ hematopoietic progenitor cells toward distinct dendritic cell subsets of the birbeck granule and MIIC-positive Langerhans cell and the interdigitating dendritic cell type.

Herbst B, Köhler G, Mackensen A, Veelken H, Kulmburg P, Rosenthal FM, Schaefer HE, Mertelsmann R, Fisch P, Lindemann A.

Blood. 1996 Oct 1;88(7):2541-8.


Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway.

Hsu HS, Lin JH, Hsu TW, Su K, Wang CW, Yang KY, Chiou SH, Hung SC.

Lung Cancer. 2012 Feb;75(2):167-77. doi: 10.1016/j.lungcan.2011.07.001. Epub 2011 Jul 28.


CD34+ cell-derived CD14+ precursor cells develop into Langerhans cells in a TGF-beta 1-dependent manner.

Jaksits S, Kriehuber E, Charbonnier AS, Rappersberger K, Stingl G, Maurer D.

J Immunol. 1999 Nov 1;163(9):4869-77.


Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.

Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, Ackland L, Ahmed N.

Br J Cancer. 2009 Jan 13;100(1):134-44. doi: 10.1038/sj.bjc.6604794. Epub 2008 Dec 16.


Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres.

Mukthavaram R, Ouyang X, Saklecha R, Jiang P, Nomura N, Pingle SC, Guo F, Makale M, Kesari S.

J Transl Med. 2015 Aug 18;13:269. doi: 10.1186/s12967-015-0627-5.


High susceptibility of c-KIT+CD34+ precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model.

van de Ven R, Verbrugge SE, Reurs AW, Bontkes HJ, Hooijberg E, Jansen G, Scheper RJ, Scheffer GL, de Gruijl TD.

Cancer Immunol Immunother. 2011 Jul;60(7):943-51. doi: 10.1007/s00262-011-1003-9. Epub 2011 Mar 24.


Characterization of dendritic cell differentiation pathways from cord blood CD34(+)CD7(+)CD45RA(+) hematopoietic progenitor cells.

Canque B, Camus S, Dalloul A, Kahn E, Yagello M, Dezutter-Dambuyant C, Schmitt D, Schmitt C, Gluckman JC.

Blood. 2000 Dec 1;96(12):3748-56.


Interleukin-6-induced JAK2/STAT3 signaling pathway in endothelial cells is suppressed by hemodynamic flow.

Ni CW, Hsieh HJ, Chao YJ, Wang DL.

Am J Physiol Cell Physiol. 2004 Sep;287(3):C771-80. Epub 2004 May 19.


Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets.

Majka M, Ratajczak J, Villaire G, Kubiczek K, Marquez LA, Janowska-Wieczorek A, Ratajczak MZ.

Exp Hematol. 2002 Jul;30(7):751-60.


Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells.

Strunk D, Rappersberger K, Egger C, Strobl H, Krömer E, Elbe A, Maurer D, Stingl G.

Blood. 1996 Feb 15;87(4):1292-302.


Withdrawal of TNF-alpha after the fifth day of differentiation of CD34+ cord blood progenitors generates a homogeneous population of Langerhans cells and delays their maturation.

Noirey N, Staquet MJ, Gariazzo MJ, Serres M, Dezutter-Dambuyant C, André C, Schmitt D, Vincent C.

Exp Dermatol. 2003 Feb;12(1):96-105.


Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.

Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A, Nogami M, Yagoto M, Ito I, Oishi T, Watanabe R, Mitsuya K, Matsuno K, Furuya T, Okawara T, Otsuka M, Ogo N, Asai A, Nakasu Y, Yamaguchi K, Akiyama Y.

Int J Oncol. 2013 Jul;43(1):219-27. doi: 10.3892/ijo.2013.1916. Epub 2013 Apr 23.


Supplemental Content

Support Center